SCHEDULE: Nantahala Capital Discloses 9.39% Stake in Avalo Therapeutics

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 9.39% beneficial ownership stake in Avalo Therapeutics, Inc. as of September 30, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack collectively reported beneficial ownership of 1,235,000 shares of Avalo Therapeutics, Inc. common stock.
• This ownership represents 9.39% of the total class of securities outstanding.
• The shares are held by funds and separately managed accounts under Nantahala's control.
• The reporting persons share both voting and dispositive power over all 1,235,000 shares, with no sole voting or dispositive power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Avalo Therapeutics.
• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, has the right to receive or direct the receipt of dividends from, or proceeds from the sale of, more than five percent of the outstanding shares beneficially owned by Nantahala.

Sentiment

Score: 7

Explanation: The disclosure of a nearly 10% passive stake by a reputable investment firm like Nantahala Capital Management suggests a positive long-term view on Avalo Therapeutics, which can be a favorable signal to the market.

Positives

• A significant institutional investor, Nantahala Capital Management, has taken a substantial 9.39% passive stake in Avalo Therapeutics, indicating confidence in the company's long-term prospects.
• The investment is stated to be in the ordinary course of business, suggesting a strategic, non-activist position.

Negatives

• No specific negative information about Avalo Therapeutics is disclosed in this ownership filing.

Risks

• The filing itself does not detail specific risks related to Avalo Therapeutics' operations or financial health, as it is an ownership disclosure.
• The primary risk related to this filing is the potential for future changes in the reporting persons' ownership stake, which could impact market perception.

Future Outlook

This filing is an ownership disclosure and does not provide forward-looking statements or guidance regarding Avalo Therapeutics' future performance or strategic direction.

Management Comments

• The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

The disclosure of a significant passive stake by an investment adviser like Nantahala Capital Management in a therapeutics company is a common occurrence in the biotechnology and pharmaceutical sectors, where institutional investors often take positions based on long-term growth potential or specific pipeline developments. It signals institutional interest in Avalo Therapeutics within the broader healthcare investment landscape.

Comparison to Industry Standards

• Not applicable, as this filing primarily concerns an ownership disclosure rather than operational or financial results that can be benchmarked against industry peers or specific comparable companies/projects.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may instill confidence and potentially attract further investment, positively impacting share price.
• Management: The presence of a large passive investor could lead to increased scrutiny or engagement, though the filing explicitly states no intent to influence control.

Next Steps

• The filing does not outline any specific future actions or milestones for Avalo Therapeutics or the reporting persons beyond the ongoing passive investment.

Key Dates

Recommendation

This Schedule 13G filing indicates a significant passive investment by Nantahala Capital Management in Avalo Therapeutics. While the substantial stake (9.39%) by a reputable institutional investor is a positive signal of confidence, the filing itself does not provide new operational or financial data to warrant a 'buy' or 'sell' recommendation. It primarily confirms an existing or updated ownership position. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of Avalo Therapeutics' business, financials, and strategic developments.

Keywords

Avalo Therapeutics, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Schedule 13G, Beneficial ownership, Common Stock, Institutional investment, Passive stake, Biotechnology